Retraction Note: HMGB1: A novel protein that induced platelets active and aggregation via Toll-like receptor-4, NF-ΚB and cGMP dependent mechanisms. [BMC Diagn Pathol. (2015), 10 (134)] DOI: 10.1186/s13000-015-0348-3;HMGB1: A novel protein that induced platelets active and aggregation via Toll-like receptor-4, NF-κB and cGMP dependent mechanisms

Diagnostic Pathology

Volumn 10, Issue 1, 2015, Pages

  Yang, Xinyu ^a   Wang, Haichao ^b   Zhang, Menmen ^c   Liu, Jin ^a   Lv, Ben ^a,b   Chen, Fangping ^a,c  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

^c CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

HMGB1; Platelet aggregation; Thrombosis

Indexed keywords

CYCLIC GMP; HIGH MOBILITY GROUP B1 PROTEIN; HMGB1 PROTEIN, HUMAN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; TLR4 PROTEIN, HUMAN; TOLL LIKE RECEPTOR 4;

ADULT; BLOOD CLOTTING DISORDER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; HUMAN; METABOLISM; PHYSIOLOGY; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; WESTERN BLOTTING;

ADULT; BLOOD COAGULATION DISORDERS; BLOOD PLATELETS; BLOTTING, WESTERN; CYCLIC GMP; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; HMGB1 PROTEIN; HUMANS; NF-KAPPA B; PLATELET ACTIVATION; PLATELET AGGREGATION; TOLL-LIKE RECEPTOR 4;

EID: 84938598929     PISSN: None     EISSN: 17461596     Source Type: Journal    
DOI: 10.1186/s13000-018-0747-3     Document Type: Erratum

References (42)

1. Margetic S. Inflammation and hemostasis [J]. Biochemia Medica. 2012;22(1):49-62.
2. Poredos P, Jezovnik MK. The role of inflammation in venous thromboembolism and the link between arterial and venous thrombosis [J]. Int Angiol. 2007;26(4):306.
3. Strukova S. Blood coagulation-dependent inflammation. Coagulation-dependent inflammation and inflammation-dependent thrombosis [J]. Front Biosci. 2005;11:59-80.
4. Müller S, Scaffidi P, Degryse B, Bonaldi T, Ronfani L, Agresti A, et al. The double life of HMGB1 chromatin protein: architectural factor and extracellular signal [J]. EMBO J. 2001;20(16):4337-40.
5. Štros M. HMGB proteins: interactions with DNA and chromatin [J]. Biochimica et Biophysica Acta (BBA)-Gene Regulatory Mechanisms. 2010;1799(1):101-13.
6. Wang H, Antoine DJ, Andersson U, Tracey KJ. The many faces of HMGB1: molecular structure-functional activity in inflammation, apoptosis, and chemotaxis [J]. J Leukoc Biol. 2013;93(6):865-73.
7. Harris HE, Andersson U, Pisetsky DS. HMGB1: a multifunctional alarmin driving autoimmune and inflammatory disease [J]. Nat Rev Rheumatol. 2012;8(4):195-202.
8. Yang H, Wang H, Tracey KJ. HMG-1 rediscovered as a cytokine [J]. Shock. 2001;15(4):247-53.
9. Lu B, Nakamura T, Inouye K, Li J, Tang Y, Lundbäck P, et al. Novel role of PKR in inflammasome activation and HMGB1 release [J]. Nature. 2012;488(7413):670-4.
10. Park JS, Gamboni-Robertson F, He Q, Svetkauskaite D, Kim JY, Strassheim D, et al. High mobility group box 1 protein interacts with multiple Toll-like receptors [J]. Am J Physiol Cell Physiol. 2006;290(3):C917-24.
11. van Beijnum JR, Buurman WA, Griffioen AW. Convergence and amplification of toll-like receptor (TLR) and receptor for advanced glycation end products (RAGE) signaling pathways via high mobility group B1 (HMGB1) [J]. Angiogenesis. 2008;11(1):91-9.
12. Lv B, Wang H, Tang Y, Fan Z, Xiao X, Chen F. High mobility group box 1 protein induces tissue factor expression in vascular endothelial cells via activation of NF-κB and Egr-1 [J]. Thromb Haemost. 2009;102(2):352.
13. Hashimoto T, Ishii J, Kitagawa F, Yamada S, Hattori K, Okumura M, et al. Circulating high-mobility group box 1 and cardiovascular mortality in unstable angina and non-ST-segment elevation myocardial infarction [J]. Atherosclerosis. 2012;221(2):490-5.
14. von Hundelshausen P, Weber C. Platelets as immune cells bridging inflammation and cardiovascular disease [J]. Circ Res. 2007;100(1):27-40.
15. Beaulieu LM, Freedman JE. The role of inflammation in regulating platelet production and function: Toll-like receptors in platelets and megakaryocytes [J]. Thromb Res. 2010;125(3):205-9.
16. Gawlowski T, Stratmann B, Ruetter R, Buenting CE, Menart B, Weiss J, et al. Advanced glycation end products strongly activate platelets [J]. Eur J Nutr. 2009;48(8):475-81.
17. Semeraro F, Ammollo CT, Morrissey JH, Dale GL, Friese P, Esmon NL, et al. Extracellular histones promote thrombin generation through platelet-dependent mechanisms: involvement of platelet TLR2 and TLR4 [J]. Blood. 2011;118(7):1952-61.
18. Rouhiainen A, Imai S, Rauvala H, Parkkinen J. Occurrence of amphoterin (HMG1) as an endogenous protein of human platelets that is exported to the cell surface upon platelet activation [J]. Thrombosis Haemostasis Stuttgart. 2000;84(6):1087-94.
19. Wang H, Bloom O, Zhang M, Vishnubhakat JM, Ombrellino M, Che J, et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science. 1999;285:248-51.
20. Grimaldi CM, Chen F, Scudder LE, Coller BS, French DL. A Cys374Tyr homozygous mutation of platelet glycoprotein IIIa (beta 3) in a Chinese patient with Glanzmann's thrombasthenia [J]. Blood. 1996;88(5):1666-75.
21. Hatada T, Wada H, Nobori T, Okabayashi K, Maruyama K, Abe Y, et al. Plasma concentrations and importance of High Mobility Group Box protein in the prognosis of organ failure in patients with disseminated intravascular coagulation [J]. Thromb Haemost. 2005;94(5):975-9.
22. Merten M, Thiagarajan P. P-selectin expression on platelets determines size and stability of platelet aggregates [J]. Circulation. 2000;102(16):1931-6.
23. NurdenAT PDR. GeorgeJ N. Platelet membrane glycoproteins: historical perspectives [J]. J Thromb Haemost. 2006;4(1):3-9.
24. Barry S. Studies with a murine monoclonal antibody that abolishes ristocetin-induced binding of von Willebrand factor to platelets: additional evidence in support of GPIb as a platelet receptor for von Willebrand factor [J]. Blood. 1983;61(1):99.
25. Smolenski A. Novel roles of cAMP/cGMP-dependent signaling in platelets [J]. J Thromb Haemost. 2012;10(2):167-76.
26. Pierce JW, Schoenleber R, Jesmok G, Best J, Moore SA, Collins T, et al. Novel inhibitors of cytokine-induced IkappaBalpha phosphorylation and endothelial cell adhesion molecule expression show anti-inflammatory effects in vivo. J Biol Chem. 1997;272:21096-103.
27. Ito T, Kawahara K, Nakamura T, Yamada S, Nakamura T, Abeyama K, et al. High-mobility group box 1 protein promotes development of microvascular thrombosis in rats [J]. J Thromb Haemost. 2007;5(1):109-16.
28. Cohen-Sfady M, Nussbaum G, Pevsner-Fischer M, Mor F, Carmi P, Zanin-Zhorov A, et al. Heat shock protein 60 activates B cells via the TLR4-MyD88 pathway [J]. J Immunol. 2005;175(6):3594-602.
29. Johnson GB, Brunn GJ, Kodaira Y, Platt JL. Receptor-mediated monitoring of tissue well-being via detection of soluble heparan sulfate by Toll-like receptor 4 [J]. J Immunol. 2002;168(10):5233-9.
30. Tadie JM, Bae HB, Jiang S, Park DW, Bell CP, Yang H, et al. HMGB1 promotes neutrophil extracellular trap formation through interactions with Toll-like receptor 4 [J]. Am J Physiol Lung Cell Mol Physiol. 2013;304(5):L342-9.
31. Yu LX, Yan L, Yang W, Wu FQ, Ling Y, Chen SZ, et al. Platelets promote tumour metastasis via interaction between TLR4 and tumour cell-released high-mobility group box1 protein [J]. Nat Commun. 2014;5.
32. Garraud O, Cognasse F. Platelet Toll-like receptor expression: the link between "danger" ligands and inflammation [J]. Inflammation Allerg Drug Targets. 2010;9(5):322-33.
33. Berthet J, Damien P, Hamzeh-Cognasse H, Pozzetto B, Garraud O, Cognasse F. Toll-like receptor 4 signal transduction in platelets: novel pathways [J]. Br J Haematol. 2010;151(1):89-92.
34. Li Z, Delaney MK, O'Brien KA, Du X. Signaling during platelet adhesion and activation [J]. Arterioscler Thromb Vasc Biol. 2010;30(12):2341-9.
35. Begonja AJ, Gambaryan S, Geiger J, Aktas B, Pozgajova M, Nieswandt B, et al. Platelet NAD (P) H-oxidase-generated ROS production regulates aαIIbβ3-integrin activation independent of the NO/cGMP pathway [J]. Blood. 2005;106(8):2757-60.
36. Radomski MW, Palmer RM, Moncada S. An L-arginine/nitric oxide pathway present in human platelets regulates aggregation. Proc Natl Acad Sci U S A. 1990;87:5193-7.
37. Li Z, Zhang G, Feil R, Han J, Du X. Sequential activation of p38 and ERK pathways by cGMP-dependent protein kinase leading to activation of the platelet integrin aαIIbβ3 [J]. Blood. 2006;107(3):965-72.
38. Isenberg JS, Romeo MJ, Yu C, Yu CK, Nghiem K, Monsale J, et al. Thrombospondin-1 stimulates platelet aggregation by blocking the antithrombotic activity of nitric oxide/cGMP signaling [J]. Blood. 2008;111(2):613-23.
39. Jang EK, Azzam JE, Dickinson NT, Davidson MM, Haslam RJ. Roles for both cyclic GMP and cyclic AMP in the inhibition of collagen-induced platelet aggregation by nitroprusside*[J]. Br J Haematol. 2002;117(3):664-75.
40. Wu X, Mi Y, Yang H, Hu A, Zhang Q, Shang C. The activation of HMGB1 as a progression factor on inflammation response in normal human bronchial epithelial cells through RAGE/JNK/NF-κB pathway [J]. Mol Cell Biochem. 2013;380(1-2):249-57.
41. Malaver E, Romaniuk MA, D'atri LP, Pozner RG, Negrotto S, Benzadón R, et al. NF-κB inhibitors impair platelet activation responses [J]. J Thromb Haemost. 2009;7(8):1333-43.
42. Lu WJ, Lee JJ, Chou DS, Jayakumar T, Fong TH, Hsiao G, et al. A novel role of andrographolide, an NF-kappa B inhibitor, on inhibition of platelet activation: the pivotal mechanisms of endothelial nitric oxide synthase/cyclic GMP [J]. J Mol Med. 2011;89(12):1261-73.